H
Harry B. Demopoulos
Researcher at New York University
Publications - 37
Citations - 3123
Harry B. Demopoulos is an academic researcher from New York University. The author has contributed to research in topics: Spinal cord injury & Ascorbic acid. The author has an hindex of 24, co-authored 37 publications receiving 3108 citations.
Papers
More filters
Journal Article
The free radical pathology and the microcirculation in the major central nervous system disorders
Journal ArticleDOI
Free radicals in cerebral ischemia.
TL;DR: The possibility that cerebral ischemia may initiate a series of pathological free radical reactions within the membrane components of the CNS was investigated in the cat and there was a progressive decrease in the amount of detectable ascorbic acid following middle cerebral artery occlusion.
Journal ArticleDOI
Effect of naloxone on posttraumatic ischemia in experimental spinal contusion
TL;DR: It is concluded that naloxone may be useful for the treatment of spinal cord injury and had striking preservation of sensory function and somatosensory evoked potentials at 24 hours after injury.
Journal ArticleDOI
Further studies on free-radical pathology in the major central nervous system disorders: effect of very high doses of methylprednisolone on the functional outcome, morphology, and chemistry of experimental spinal cord impact injury
Harry B. Demopoulos,Eugene S. Flamm,Myron L. Seligman,Dennis D. Pietronigro,J. J. Tomasula,V. DeCrescito +5 more
TL;DR: This model system is among others in the CNS which offer distinctive opportunities to study, in vivo, the onset and progression of membrane damaging free-radical reactions within well-defined parameters of time, extent of tissue injury, correlation with changes in membrane enzymes, and correlation with readily measurable in vivo functions.
Patent
Pharmaceutical preparations of glutathione and methods of administration thereof
TL;DR: In this article, a method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathy in a rapidly dissolving formulation to a mammal on an empty stomach was presented.